ALK and non-small cell lung carcinoma: A broad therapeutic arsenal is currently available to treat ALK‐positive NSCLC tumors, and sequential treatment with different ALK‐Is is the best therapeutic option for NSCLC patients with an ALK translocation [3, 4].